FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
FibroBiologics dosed the first patients in its Phase 1/2 trial evaluating CYWC628 for diabetic foot ulcers and remains on track for interim data in the second half of 2026. The company reported a Q2 net loss of $4.1 million with cash totaling $3.5 million at quarter-end, though it recently secured $9.0 million in private placement and $3.0 million in public offering proceeds.
Key figures
- Net loss
- 4100000
- Ga expenses
- 2400000
- Rd expenses
- 1700000
- Cash equivalents
- 3500000
- Proceeds public offering
- 3000000
- Proceeds private placement
- 9000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.